sevabertinib

Action and Spectrum

Action and spectrum:    

Actions:  

Sevabertinib is an orally administered dual kinase inhibitor designed to block the activity of both the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2). It is particularly relevant for treating non–small cell lung cancer (NSCLC) that carries activating mutations in HER2. By preferentially targeting mutant forms of EGFR and HER2, the drug disrupts downstream signaling pathways driven by these receptors. This interruption can slow tumor growth, reduce angiogenesis, and may contribute to tumor shrinkage in cancers that rely on EGFR/HER2 activity. 

Drug Interaction

Adverse Reaction

Frequency Defined   

Rash 

Pneumonitis  

Diarrhea 

Black Box Warning

Black Box Warning     

None  

Contraindication / Caution

Contraindication/Caution:    

Contraindication  

Specific Genetic mutations 

Liver problems 

Pregnancy / Lactation

Pregnancy Warnings:    

Pregnancy category: N/A    

Lactation: Excretion in human breastmilk is unknown    

Pregnancy categories:    

Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.    

Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.    

Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.    

Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.    

Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.     

Category N: There is no data available for the drug under this category.     

Pharmacology

Pharmacology:    

Sevabertinib is a dual-action kinase inhibitor that blocks the function of both the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2), especially when these receptors carry certain activating mutations. By interfering with signaling pathways driven by EGFR and HER2, the drug can suppress tumor cell proliferation and angiogenesis and may contribute to the reduction of tumors that depend on EGFR/HER2 activity. 

Adminstartion

Administration:    

 The drug is taken orally. 

Patient Information Leaflet

Patient information leaflet    

Generic Name: sevabertinib 

Why do we use sevabertinib?   

Sevabertinib is mainly indicated for patients with non-small cell lung cancer (NSCLC) that carries HER2 mutations. This orally active agent functions as a dual kinase inhibitor, blocking both the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2). By suppressing the activity of these pathways, it helps hinder tumor development and the formation of new blood vessels.